ClinicalTrials.gg
RecruitingNCT06702033MINT-2Updated Jul 24, 2026

The Minimalist Trial-2

A Phase 2 interventional study of Radiation therapy and Cisplatin in HPV-Related Oropharynx Squamous Cell Carcinoma, sponsored by Washington University School of Medicine. Recruiting at 3 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-24.

Sponsored by Washington University School of Medicine · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Apr 2025; still recruiting 1 year 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
142
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 26 studies testing cisplatin in Oropharyngeal Neoplasms — 9 open to participants now, 18 under way, 5 of them phase 3. Cisplatin · Oropharyngeal Neoplasms.

Planned enrollment
9th of 26
142 · median 107
Started
2025
with 1 other
Phase 2
17 of 26
8 open now
Primary completion
2030-04
later than 16 of 17 live
Registered
26th of 26
by date

Among the 26 studies testing cisplatin in Oropharyngeal Neoplasms, this one is the 9th largest by planned enrollment, is one of 2 that started in 2025, is one of 17 in phase 2, reaches primary completion later than 16 of the 17 other live ones, and was the 26th registered.

Oropharyngeal Neoplasms

370 studies on the registry are indexed under Oropharyngeal Neoplasms; 104 are open to participants now.

Browse Oropharyngeal Neoplasms studies →

Open to participants now

9 of the 26 studies testing cisplatin in Oropharyngeal Neoplasms are open now, in 2 countries. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 9 open studies →

About cisplatin

Cisplatin: first FDA approval 1978 (PLATINOL-AQ). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 89 Oropharyngeal Neoplasms studies recruiting now, 76 (85%) set no upper age limit and 5 (6%) stop at 75 or younger; none take children under 18; 7 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 26 studies testing cisplatin in Oropharyngeal Neoplasms, or all of them as a file.
02

Study summary

Head and neck squamous cell carcinoma (HNSCC) is the sixth most common cancer. Oropharynx SCC (OPSCC) is a common sub-type of HNSCC. Each year, 16,000 new cases of OPSCC are diagnosed in the USA. Most cases of OPSCC (>90%) are caused by the human papillomavirus (HPV) and are often cured with current therapy.

However, patients treated with surgery followed by postoperative adjuvant chemotherapy and radiation therapy (POA(C)RT) still experience substantial morbidity. In this highly curable disease, current clinical research interest is focused on investigation of de-escalated therapy, with the goal to reduce treatment-related adverse events (AEs) while maintaining a low recurrence rate.

In this study, patients with HPV-related OPSCC will undergo resection of the primary tumor site and involved/at-risk regional neck nodes. Based on the pathology report, patients will be assigned to:

  • Arm 1 (de-POACRT-42 Gy)
  • Arm 2A (de-POART-42 Gy)
  • Arm 2B (de-POART-37.8 Gy)
  • Arm 2C (de-POACRT-30 Gy).

All patients with high-risk pathology will be assigned to Arm 1 whereas patients with intermediate-risk pathology will be randomized (1:1:1) to Arm 2A, Arm 2B, or Arm 2C. Patients with highest-risk pathology and low-risk pathology will be removed from the trial after surgery and will be advised to pursue standard of care options.

03

Conditions studied

  • HPV-Related Oropharynx Squamous Cell Carcinoma

Keywords

  • De-escalation
  • Adjuvant therapy
  • Oropharyngeal cancer
  • Human papillomavirus
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • or cytologically confirmed HPV-related, clinical stages I-II OPSCC (8th edition of AJCC/UICC Staging Manual) or HPV-related neck node with unknown primary. Clinical T1N0M0 and T2N0M0 disease are excluded. HPV-related may be defined by p16 IHC stain and/or HPV-High Risk RNA ISH/HPV DNA genotyping by PCR, using standard definitions of positive and negative test results.
  • Planned resection of the primary tumor site by a transoral approach (TORS, TLM, or conventional surgery).
  • Planned unilateral or contralateral selective neck dissection.
  • PS 0-2.
  • Adequate organ and marrow function defined as:

    • ≥ 50 mL/min.
    • ≥ 1.0 K/cumm.
    • count ≥100 K/cumm.
  • At least 18 years of age.
  • Women of and men must agree to use adequate (hormonal or barrier method of birth control, abstinence) prior to study entry and for the duration of participation. Should a woman become pregnant or suspect she is pregnant while participating in this study, she must inform her treating physician immediately.
  • Ability to understand and willingness to sign an IRB approved written document. Legally authorized representatives may sign and give informed consent on behalf of study participants.

Exclusion criteria

Exclusion Criteria:

  • Clinical T1N0M0 or T2N0M0 disease.
  • Prior radiation therapy for HNSCC.
  • Planned free-flap reconstruction of the resected primary site.
  • Cirrhosis with Score B or C.
  • History of prior invasive diagnosed within 2 years prior to study enrollment; exceptions are malignancies with a low risk of or death (e.g., expected 5-year OS > 90%) that were treated with curative-intent therapy.
  • Receiving any other agents.
  • Uncontrolled serious inter-current illness or serious psychiatric illness/social situations that would limit compliance with study requirements.
  • Pregnant and/or breastfeeding. A negative serum pregnancy test is required at screening for all female patients of .
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
142 participants (estimated)

Study arms

  • Experimental
    Arm 1: Radiation therapy + Cisplatin

    * Standard of care surgery will occur before adjuvant therapy. * It is recommended that radiation therapy begin within 28 to 49 days (and no later than 56 days). * The total dose to the postoperative tumor bed will be 4200 cGy in 21 fractions of 200 cGy each over 4 weeks. * Additional regions in the ipsilateral and contralateral neck at risk for microscopic disease in the cervical lymph nodes will receive 3780 cGy in 21 fractions of 180 cGy each. * Cisplatin will be given on the same day as one of the initial 5 doses of radiation therapy.

    Radiation: Radiation therapy · Drug: Cisplatin · Procedure: Surgery

  • Experimental
    Arm 2A: Radiation therapy

    * Standard of care surgery will occur before adjuvant therapy. * It is recommended that radiation therapy begin within 28 to 49 days (and no later than 56 days). * The total dose to the postoperative tumor bed will be 4200 cGy in 21 fractions of 200 cGy each over 4 weeks. * Additional regions in the ipsilateral and contralateral neck at risk for microscopic disease in the cervical lymph nodes will receive 3780 cGy in 21 fractions of 180 cGy each.

    Radiation: Radiation therapy · Procedure: Surgery

  • Experimental
    Arm 2B: Radiation therapy

    * Standard of care surgery will occur before adjuvant therapy. * It is recommended that radiation therapy begin within 28 to 49 days (and no later than 56 days). * The total dose to the postoperative tumor bed will be 3780 cGY in 21 fractions of 180 cGy each over 4 weeks. * Additional regions in the ipsilateral and contralateral neck at risk for microscopic disease in the cervical lymph nodes will receive 3360 cGy in 21 fractions of 160 cGy each.

    Radiation: Radiation therapy · Procedure: Surgery

  • Experimental
    Arm 2C: Radiation therapy + Cisplatin

    * Standard of care surgery will occur before adjuvant therapy. * It is recommended that radiation therapy begin within 28 to 49 days (and no later than 56 days). * The total dose to the postoperative tumor bed will be 3000 cGy in 15 fractions of 200 cGy over 3 weeks. * Additional regions in the ipsilateral and contralateral neck at risk for microscopic disease in the cervical lymph nodes will receive 2700 cGy in 15 fractions of 180 cGy each. * Cisplatin will be given on the same day as one of the initial 5 doses of radiation therapy.

    Radiation: Radiation therapy · Drug: Cisplatin · Procedure: Surgery

Interventions

  • RadiationRadiation therapy

    IMRT or IMPT

  • Dose of 100 mg/m\^2 IVPB over 60 minutes

  • ProcedureSurgery

    Standard of care

06

What researchers measure

Primary outcomes

  1. Recurrence rate

    Time frame: At 2 years

Secondary outcomes

  1. Percent weight loss

    For assessing percent weight loss, weight (kg) will be collected weekly during radiation within each arm, starting at Day 1 of RT and ending on the last day of RT. The percent weight loss from the baseline is calculated at any post-baseline.

    Time frame: From start of radiation therapy to completion of radiation therapy (estimated to be 6 weeks)

  2. Proportion of patients undergoing PEG tube placement

    Time frame: Through completion of follow-up (estimated to be 5 years and 10 weeks)

  3. Duration of need for an indwelling PEG tube

    Time frame: Through completion of follow-up (estimated to be 5 years and 10 weeks)

  4. Proportion of patients taking narcotic

    Time frame: Through completion of follow-up (estimated to be 5 years and 10 weeks)

  5. Number of participants with adverse events

    Time frame: From start of surgery through 24-month follow-up visit (estimated to be 2 years and 10 weeks)

  6. Mean change in serum creatinine during radiation therapy

    Serum creatinine levels are collected at Day 1 of RT and ending on the last day of RT.

    Time frame: From start of radiation therapy to completion of radiation therapy (estimated to be 6 weeks)

  7. Progression-free survival (PFS)

    PFS will be calculated from the date of surgery to the date of progression, death of any cause, or last known date alive.

    Time frame: Through completion of follow-up (estimated to be 5 years and 10 weeks)

  8. Overall survival (OS)

    OS will be calculated from the date of surgery to the date of death or last known date alive.

    Time frame: Through completion of follow-up (estimated to be 5 years and 10 weeks)

07

Study locations

3 of 3 sites recruiting
  • Washington University School of Medicine
    St Louis, Missouri 63110, United States
    Recruiting
    • Douglas Adkins, M.D. · Contactdadkins@wustl.edu · 314-747-8475
    • Douglas Adkins, M.D. · Principal investigator
    • Peter Oppelt, M.D. · Sub investigator
    • Anthony J Apicelli, M.D., Ph.D. · Sub investigator
    • Jennifer De Los Santos, M.D. · Sub investigator
    • Christine Auberle, M.D. · Sub investigator
    • Nikhil Rammohan, M.D., Ph.D. · Sub investigator
    • Wade Thorstad, M.D. · Sub investigator
    • R. Alex Harbison, M.D., M.S. · Sub investigator
    • Ryan Jackson, M.D. · Sub investigator
    • Patrik Pipkorn, M.D. · Sub investigator
    • Sid Puram, M.D., Ph.D. · Sub investigator
    • Jason Rich, M.D. · Sub investigator
    • Esther Lu, Ph.D. · Sub investigator
    • Sana Karam, M.D., Ph.D. · Sub investigator
    • Brendan Knapp, M.D. · Sub investigator
    • Jesse Zaretsky, M.D., Ph.D. · Sub investigator
    • Ben Wahle, M.D. · Sub investigator
  • Sanford Roger Maris Cancer Center
    Fargo, North Dakota 58102, United States
    Recruiting
    • Daniel Almquist, M.D. · Contact701-234-6161
    • Daniel Almquist, M.D. · Principal investigator
  • Sanford Cancer Center
    Sioux Falls, South Dakota 57104, United States
    Recruiting
    • Steven Powell, M.D. · Contact605-328-8000
    • Steven Powell, M.D. · Principal investigator
08

References and documents

Individual participant data

Plan to share: Yes — Individual participant data that underlie the results reported in this article, after de-identification (text, tables, figures, and appendices), and the study protocol will be shared, beginning 9 months and ending 24 months following article publication, with investigators whose proposed use of the data has been approved by an independent review committee ("learned intermediary") identified for this purpose. Types of acceptable analyses include approved proposal(s) or individual participant data for meta-analyses.

Supporting information: Study protocol

Time frame: Beginning 9 months and ending 24 months following article publication.

Access criteria: Information regarding submitting proposals and accessing data may be submitted to jcley@wustl.edu.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2025 (actual). Primary completion is estimated for Apr 2030, 60 months after the start.

Of 63 non-industry phase 2 interventional studies under Oropharyngeal Neoplasms, half reached primary completion within 60 months of starting (the median), counting those still running; a quarter within 49 and three quarters within 99. This study's planned 60 months is close to that.

Counting every sponsor, half of 64 studies reached it within 63 months; a quarter within 49 and three quarters within 99.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 19, 2024
First posted
Nov 22, 2024
StartActual
Apr 10, 2025
Primary completionEst.
Apr 30, 2030
CompletionEst.
Jul 15, 2033
Last update
Jul 24, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 24, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06702033
Collaborators
The Joseph Sanchez Foundation
Responsible party
Sponsor
First posted
Nov 22, 2024
Start date
Apr 10, 2025
Primary completion
Apr 30, 2030 (estimated)
Completion
Jul 15, 2033 (estimated)
Last update
Jul 24, 2026

Study contacts

Douglas Adkins, M.D.
Contact
dadkins@wustl.edu
314-747-8475
Douglas Adkins, M.D.
principal investigator · Washington University School of Medicine

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cisplatin

Start the discussion